Research on sacituzumab govitecan, also known as Trodelvy, has yielded updates on its uses in cancer treatment, particularly for triple-negative breast cancer. The treatment has been found to have fewer severe side effects compared to chemotherapy in some patients with untreated triple-negative breast cancer. The medication's benefits and uses are being further explored in various studies and trials, including a phase 3 trial for metastatic triple-negative breast cancer.